| Year |
Citation |
Score |
| 2021 |
Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu EY, Frissora FW, Mo XM, Walker LA, Yan PS, Bundschuh R, Beaver L, Devine RD, Tsai YT, Ventura AM, ... ... Grieselhuber NR, et al. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia. Blood. PMID 34788382 DOI: 10.1182/blood.2020010344 |
0.394 |
|
| 2019 |
Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, et al. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Advances. 3: 242-255. PMID 30692102 DOI: 10.1182/bloodadvances.2018024182 |
0.337 |
|
| 2018 |
Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, et al. BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. Cancer Discovery. PMID 29386193 DOI: 10.1158/2159-8290.Cd-17-0902 |
0.399 |
|
| 2018 |
Mitchell SR, Grieselhuber N, Asemelash Y, Cannon M, Orwick S, Sharma P, Goettl V, Puduvalli VK, Sampath D, Mims AS, Blachly JS, Lehman AM, Harrington BK, Breitbach J, Baloglu E, et al. NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia Blood. 132: 3931-3931. DOI: 10.1182/blood-2018-99-119358 |
0.342 |
|
| 2018 |
Larkin K, Guth E, Harrington BK, Grieselhuber N, Muthusamy N, Byrd JC. CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy Blood. 132: 4056-4056. DOI: 10.1182/Blood-2018-99-117262 |
0.305 |
|
| 2016 |
Grieselhuber NR, Mitchell SR, Orwick S, Harrington BK, Goettl VM, Walker AR, Bhatnagar B, Mims AS, Klisovic RB, Vasu S, Blum W, Blachly JS, Lucas DM, Garzon R, Lapalombella R, et al. The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia Blood. 128: 3941-3941. DOI: 10.1182/BLOOD.V128.22.3941.3941 |
0.388 |
|
| 2013 |
Grieselhuber NR, Klco JM, Verdoni AM, Lamprecht T, Sarkaria SM, Wartman LD, Ley TJ. Notch signaling in acute promyelocytic leukemia. Leukemia. 27: 1548-57. PMID 23455394 DOI: 10.1038/Leu.2013.68 |
0.547 |
|
| 2011 |
Grieselhuber NR, Klco JM, Verdoni AM, Ley TJ. Activation of Notch Signaling Is An Early Event in the Development of PML-Rara-Induced Acute Promyelocytic Leukemia (APL) Blood. 118: 2468-2468. DOI: 10.1182/Blood.V118.21.2468.2468 |
0.602 |
|
| 2010 |
Uy GL, Lane AA, Welch JS, Grieselhuber NR, Payton JE, Ley TJ. A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood. 116: 3604-10. PMID 20647568 DOI: 10.1182/Blood-2008-11-189282 |
0.52 |
|
| 2009 |
Payton JE, Grieselhuber NR, Chang LW, Murakami M, Geiss GK, Link DC, Nagarajan R, Watson MA, Ley TJ. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. The Journal of Clinical Investigation. 119: 1714-26. PMID 19451695 DOI: 10.1172/Jci38248 |
0.616 |
|
| 2009 |
Grieselhuber NR, Shaik JS, Chang L, McGrath S, Wartman LD, Nagarajan R, Wilson RK, Mardis E, Ley TJ. Chromatin Immunoprecipitation of GFP-Tagged PML-Rara Coupled to High-Throughput Next Generation Sequencing. Blood. 114: 1276-1276. DOI: 10.1182/Blood.V114.22.1276.1276 |
0.564 |
|
| 2007 |
Payton JE, Grieselhuber NR, Chang L, Murakami MA, Yuan W, Link DC, Nagarajan R, Watson MA, Ley TJ. The Expression Signature of M3 AML Suggests Direct and Indirect Effects of PML-RARA on Target Genes. Blood. 110: 719-719. DOI: 10.1182/Blood.V110.11.719.719 |
0.631 |
|
| 2005 |
Yuan W, Grieselhuber NR, Green RD, Ley TJ. Identification of PML-RARa Target Genes Using Microarray and ChIP-on-Chip Analysis. Blood. 106: 2994-2994. DOI: 10.1182/Blood.V106.11.2994.2994 |
0.644 |
|
| Show low-probability matches. |